Promising new treatment option for chronic plaque psoriasis
Tuesday, June 6, 2017 - 11:22
in Health & Medicine
A new study tested the efficacy of tildrakizumab, an antibody that targets only a very specific immune system pathway. More than 60 percent of all patients who received the active medication showed improvement, compared to less than 10 percent of patients who received placebos.